Fulcrum's Phase 3 for old GSK drug fails, stock sinks
Fulcrum Therapeutics reported a Phase 3 fail Thursday morning, sending its stock plummeting.
The biotech said that a study testing the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
